MeSH term
Frequency | Condition_Probility | Adolescent | 11 | 0.0 |
Adult | 18 | 0.0 |
Child | 7 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Female | 17 | 0.0 |
Gene Expression | 2 | 0.0 |
Humans | 42 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Male | 22 | 0.0 |
Middle Aged | 12 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 2 | 1.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Repressor Proteins/*genetics/metabolism | 2 | 3.0 |
Research Support, Non-U.S. Gov't | 32 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
Base Sequence | 16 | 0.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Keratin/analysis | 2 | 0.0 |
Molecular Sequence Data | 24 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 10 | 5.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Gene Library | 3 | 0.0 |
Hela Cells | 4 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Chromosomes, Human, Pair 18 | 6 | 5.0 |
Sarcoma, Synovial/chemistry/*genetics | 3 | 100.0 |
X Chromosome | 6 | 1.0 |
Amino Acid Sequence | 16 | 0.0 |
Cell Line | 3 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Proteins/*chemistry/*metabolism | 2 | 6.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Animals | 8 | 0.0 |
Sarcoma, Synovial/*diagnosis/genetics/pathology | 3 | 100.0 |
Cell Division | 2 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
Aged | 11 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Karyotyping | 3 | 0.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Oncogene Proteins, Fusion/genetics | 3 | 3.0 |
Proteins/genetics | 3 | 0.0 |
Repressor Proteins/genetics | 4 | 2.0 |
Binding Sites | 2 | 0.0 |
Mice | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Down-Regulation | 2 | 0.0 |
Exons | 2 | 0.0 |
Oncogene Proteins, Fusion/*genetics/metabolism | 2 | 9.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Sarcoma, Synovial/*genetics | 7 | 46.0 |
Sequence Alignment | 6 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Tumor Markers, Biological/genetics | 3 | 3.0 |
Proteins/*genetics | 6 | 0.0 |
Sarcoma, Synovial/*genetics/pathology | 3 | 75.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Translocation, Genetic/genetics | 2 | 2.0 |
Prognosis | 3 | 0.0 |
Survival Analysis | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Transfection | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Gene Fusion | 2 | 2.0 |
Sarcoma, Synovial/*genetics/metabolism/pathology | 2 | 66.0 |
*Translocation, Genetic | 9 | 1.0 |
*Chromosomes, Human, Pair 18 | 4 | 2.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
Paraffin Embedding | 2 | 0.0 |
Repressor Proteins/*genetics | 9 | 3.0 |
*X Chromosome | 4 | 0.0 |
Sarcoma, Synovial/*genetics/mortality/pathology | 2 | 100.0 |
Survival Rate | 2 | 0.0 |
Chromosomes, Human, Pair 18/*genetics/ultrastructure | 2 | 22.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
X Chromosome/*genetics/ultrastructure | 2 | 28.0 |
RNA, Neoplasm/*analysis | 3 | 6.0 |
*Neoplasm Proteins | 6 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
DNA Primers | 2 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
